Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542743 | 1.00 | CYP4F2 (0.50) | CYP4F2CYP4A11PARP1ALDH1A1AR | |
| SCHEMBL30600807 | 0.86 | SMYD3 (0.52) | PARP1ALDH1A1ARACACBMAPK1 | |
| SCHEMBL5234628 | 0.86 | SMYD3 (0.52) | PARP1ALDH1A1ARACACBMAPK1 | |
| SCHEMBL29479667 | 0.85 | PARP1 (0.50) | PARP1ALDH1A1ARACACBMAPK1 | |
| SCHEMBL502256 | 0.85 | PARP1 (0.50) | PARP1ALDH1A1ARACACBMAPK1 | |
| SCHEMBL480291 | 0.84 | CYP4F2 (0.52) | CYP4F2CYP4A11ALDH1A1MAPK1KDM4E | |
| SCHEMBL4441732 | 0.83 | LOXL2 (0.55) | PARP1ALDH1A1ARACACBSMYD3 | |
| SCHEMBL127718 | 0.83 | PARP1 (0.49) | PARP1ALDH1A1ARACACBMAPK1 | |
| SCHEMBL30740810 | 0.83 | ALDH1A1 (0.50) | PARP1ALDH1A1ARACACBMAPK1 | |
| SCHEMBL7083009 | 0.83 | PARP1 (0.49) | PARP1ALDH1A1ARACACBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4482839-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20220267298-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-08-25 | — | — | US | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021018948-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | WO | disclosed |
| EP-2686305-B1 | QUINAZOLINEDIONES AND THEIR USE | IMPACT THERAPEUTICS INC (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10188653-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2014031928-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2012125521-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2010007800-A1 | NOVEL URACIL COMPOUND HAVING AMIDE STRUCTURE AND SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | PAYNE LINDA S (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1196384-A4 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1196384-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000578-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | STING1, IRF3, CGAS | CYP4F2 4590/4885CYP4A11 3064/4885PARP1 1850/4885 |
| US-20220267298-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK4, GRK3 | CYP4F2 966/4885CYP4A11 956/4885PARP1 2761/4885 |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CYP4F2 1159/4885CYP4A11 535/4885PARP1 2835/4885 |
| US-10188653-B2 | Diacylglycerol acyltransferase 2 inhibitors | DGAT2, LCLAT1, DGAT1 | CYP4F2 1738/4885CYP4A11 3079/4885PARP1 2860/4885 |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | CYP2S1, IMPDH1, IDO1 | CYP4F2 1592/4885CYP4A11 595/4885PARP1 335/4885 |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | PARP1, PARP15, PARP11 | CYP4F2 1024/4885CYP4A11 723/4885PARP1 1/4885 |
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CYP4F2 3246/4885CYP4A11 2240/4885PARP1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.